Loading clinical trials...
Loading clinical trials...
Open-label Randomized Crossover Two Period Single Dose Bioequivalence Study of Two Formulations Ramipril Tablets 10 mg (Pharmtechnology LLC, Republic of Belarus) and Tritace® Tablets 10 mg (Sanofi-Aventis Deutschland GmbH, Germany) in Healthy Volunteers Under Fasting Conditions
Conditions
Interventions
Ramipril tablet 10 mg
Tritace® tablet 10 mg
Locations
1
Russia
Ligand Research LLC
Moscow, Russia
Start Date
June 17, 2022
Primary Completion Date
August 2, 2022
Completion Date
November 17, 2022
Last Updated
June 29, 2023
NCT07345130
NCT06969963
NCT06924190
NCT06830954
NCT06758531
NCT06600282
Lead Sponsor
Pharmtechnology LLC
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions